Eli Lilly recently won its third straight trial over the withdrawal risks of its antidepressant Cymbalta, persuading a federal jury that warnings on the drug were adequate. Defense attorneys say this key finding gives the drugmaker an edge in an upcoming fight with plaintiffs trying to consolidate dozens of similar suits.
Litigation partner William Hoffman weighed in on Lilly's recent successes for Law360:
"From my perspective watching this litigation, this company has a strong defense that's being well-presented, that there is strong labeling for this product and that it's giving them the upper hand with judges considering summary judgment motions and at trial. That's going to weigh heavily on the JPML panel, since it has already rejected an earlier consolidation petition."
Also of Interest
- Benchmark Litigation Recognizes Kaye Scholer Practices and Partners Nationwide October 24, 2016 • Recognitions
- What’s Really Remarkable about the Appeals Court Ruling on the CFPB October 20, 2016 • Articles
- Winning the War: Strategies for Prevailing in Consumer Fraud and False Advertising... October 17, 2016 • Articles
- Kaye Scholer Clients Achieve Nearly Full Recovery in Arch Coal Chapter 11 Proceeding October 14, 2016 • Client Successes
- 3D Printing: New Legal Issues Emerge with the Technology’s Revolutionary Potential October 10, 2016 • Articles
- Consumer Products in the Age of Big Data October 4, 2016 • Articles
- Antitrust Jurisprudence in the Second Circuit October 1, 2016 • Articles
- And Now A Word From The Panel: 3 Alternatives To MDLs September 28, 2016 • Articles
- Kaye Scholer Represents Investors in Volkswagen Diesel Emissions Litigation September 28, 2016 • Client Successes